Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

330
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
330
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

267
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
267
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

462
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
462
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

64
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
64
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

101
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
101
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

315
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
315

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Holding On or Letting Go: Immunosuppression After Pediatric Kidney Allograft Failure.

Pediatric transplantation·2026
Same author

Provider Perspectives on the Role of Hypotension in Pediatric Kidney Transplant: A Pediatric Nephrology Research Consortium Study.

Pediatric transplantation·2026
Same author

Does the Baxter cycler pull fluid from accessory bags in series or in parallel?

Pediatric nephrology (Berlin, Germany)·2025
Same author

Diseases of the primary cilia: a clinical characteristics review.

Pediatric nephrology (Berlin, Germany)·2024
Same author

Clinicopathological characteristics of pediatric ANCA-associated glomerulonephritis.

Pediatric nephrology (Berlin, Germany)·2024
Same author

Safety and infectious outcomes in pediatric kidney transplant recipients after COVID-19 vaccination: A pediatric nephrology research consortium study.

Pediatric transplantation·2024

Related Experiment Video

Updated: Sep 19, 2025

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.5K

Acute interstitial nephritis associated with ondansetron.

Olga Charnaya1, Elizabeth Goswami2

  • 1Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ocharna1@jhmi.edu.

Pediatric Nephrology (Berlin, Germany)
|June 2, 2025
PubMed
Summary

A 16-year-old experienced acute kidney injury after ondansetron use. Kidney function improved after medication withdrawal, highlighting ondansetron

Keywords:
5HT3 blockageAcute kidney injuryInterstitial nephritisOndansetron

More Related Videos

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.1K
Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
04:37

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

792

Related Experiment Videos

Last Updated: Sep 19, 2025

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.5K
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.1K
Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
04:37

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

792

Area of Science:

  • Nephrology
  • Clinical Pharmacology

Background:

  • Acute kidney injury (AKI) can present with diverse etiologies.
  • Medication-induced nephrotoxicity is a significant concern in adolescent health.

Purpose of the Study:

  • To report a case of severe kidney dysfunction potentially linked to ondansetron in a 16-year-old male.
  • To investigate the association between ondansetron exposure and acute kidney injury.

Main Methods:

  • Case report of a 16-year-old male with seizure and severe kidney dysfunction.
  • Clinical observation of kidney function following medication review and withdrawal.
  • Analysis of patient's exposure history, including ondansetron and ibuprofen.

Main Results:

  • The patient presented with severe kidney dysfunction and dilute urine.
  • Kidney function significantly improved after discontinuation of all prior medications, including ondansetron.
  • Recurrence of kidney dysfunction after a subsequent dose of ondansetron, with normalization upon withdrawal.

Conclusions:

  • Ondansetron may be associated with acute kidney injury in adolescents.
  • Prompt recognition and withdrawal of the offending agent are crucial for kidney function recovery.
  • Further investigation into ondansetron's nephrotoxic potential is warranted.